new
coronaviru
also
known
infect
patient
becom
global
health
emerg
due
high
risk
spread
impact
specif
drug
vaccin
thu
effect
antivir
agent
still
urgent
need
combat
viru
herein
fep
free
energi
perturb
base
screen
strategi
newli
deriv
rapid
protocol
accur
reposit
potenti
agent
target
viral
proteinas
mpro
restrain
energi
distribut
red
function
deriv
optim
alchem
pathway
fep
greatli
acceler
calcul
first
made
fep
possibl
virtual
screen
fdaapprov
drug
databas
result
fifteen
twentyf
drug
valid
vitro
exhibit
consider
inhibitori
potenc
toward
mpro
among
potent
mpro
inhibitor
dipyridamol
potenti
inhibit
signal
pathway
inflammatori
respons
finish
first
round
clinic
trial
result
demonstr
fepbas
screen
show
remark
advantag
prompt
drug
reposit
novel
coronaviru
also
known
outbreak
emerg
wuhan
hubei
provinc
china
decemb
march
confirm
case
includ
death
china
viru
also
infect
patient
contin
countri
itali
spain
usa
germani
franc
iran
gradual
becam
global
pandem
due
high
risk
spread
impact
date
specif
treatment
vaccin
thu
urgent
need
reposit
potenti
agent
covid
replicas
gene
encod
two
overlap
translat
product
polyprotein
mediat
function
requir
viral
replic
mpro
key
enzym
proteolyt
process
viral
replic
initi
releas
autocleavag
mpro
turn
cleav
releas
function
protein
necessari
viral
replic
view
essenti
function
mpro
viral
life
cycl
high
conservat
attract
target
discoveri
agent
great
effort
variou
research
group
done
discov
new
agent
sever
databas
target
target
mpro
via
sever
virtual
screen
strategi
consist
pharmacophor
molecul
dock
molecular
simul
approach
result
six
drug
inhibit
mpro
valu
rang
drug
design
method
contribut
consider
lead
discoveri
comput
accuraci
effici
need
improv
especi
deal
emerg
situat
outbreak
free
energi
perturb
fep
method
promis
method
satisfactori
accuraci
actual
applic
drug
design
still
limit
simul
minor
structur
chang
ligand
thu
predict
rel
bind
free
energi
rbfe
order
perform
virtual
screen
larg
molecul
databas
absolut
bind
free
energi
abf
calcul
must
perform
ligand
without
use
refer
ligand
structur
fep
approach
advantag
predict
affin
precis
drug
target
convent
method
pharmacophor
molecul
dock
molecular
simul
howev
fepabf
approach
extrem
expensivetimeconsumpt
therefor
use
virtual
screen
purpos
acceler
discoveri
mpro
inhibitor
small
molecul
databas
combat
repres
newli
deriv
fepabfeacceler
screen
strategi
togeth
bioassay
valid
rapidli
reposit
potenti
agent
target
viral
proteinas
mpro
result
fifteen
twentyf
drug
valid
vitro
exhibit
consider
inhibitori
potenc
toward
mpro
among
potent
repres
mpro
inhibitor
dipyridamol
finish
firstround
clinic
trial
show
signific
clinic
outcom
short
first
report
screen
fdaapprov
databas
use
fepabf
approach
fepbas
method
show
signific
advantag
mean
improv
hit
rate
reposit
potent
lead
crystal
structur
viral
proteinas
mpro
pdb
id
use
molecul
dock
purpos
base
crystal
structur
small
molecul
fdaapprov
drug
databas
first
screen
use
molecular
dock
program
glide
consid
mpro
proteas
act
nucleophil
agent
acid
assist
hydrolysi
reaction
substrat
protein
form
hydrogen
bond
structur
backbon
substrat
protein
thu
residu
consid
key
residu
mpro
screen
dock
bind
mode
ligand
care
check
molecul
specif
interact
key
residu
rel
high
dock
score
select
fep
studi
evalu
abf
ligand
select
molecular
dock
evalu
fep
calcul
carri
fep
calcul
ns
preliminari
md
simul
perform
receptorligand
complex
improv
fit
ligand
bind
pocket
ligand
parameter
gener
amber
forc
field
gaff
restrain
electrostat
potenti
resp
charg
calcul
rel
ligand
perform
gaussian
program
level
paramet
protein
describ
amber
forc
field
model
use
water
molecul
system
neutral
ad
counter
ion
either
na
clion
system
first
minim
use
steepest
descent
method
cycl
heat
k
nvt
ensembl
within
ps
system
equilibr
npt
ensembl
weak
restraint
kjmolnm
ps
follow
ns
unconstrain
product
simul
last
snapshot
md
simul
use
follow
fep
calcul
trajectori
last
ns
analyz
get
paramet
ad
restraint
receptor
ligand
base
preliminari
md
simul
result
fepabf
calcul
carri
base
thermodynam
cycl
given
figur
shown
thermodynam
cycl
restraint
ad
receptor
ligand
fep
calcul
strategi
ad
restraint
first
report
boresch
et
al
use
studi
consist
one
distanc
two
angl
three
dihedr
harmon
potenti
forc
constant
rad
contribut
restraint
lig
system
calcul
analyt
contribut
restraint
reclig
system
calcul
fep
accord
strategi
three
atom
ligand
three
atom
receptor
select
add
restraint
order
add
restraint
equilibrium
posit
program
design
automat
detect
requir
paramet
select
three
ligand
atom
three
receptor
atom
ligand
heavi
atom
closest
geometri
center
select
first
atom
heavi
atom
distant
first
atom
select
second
atom
heavi
atom
form
angl
larger
degre
first
two
atom
distant
first
atom
select
third
atom
receptor
base
last
ns
trajectori
ns
preliminari
md
simul
distanc
angl
dihedr
three
ligand
atom
cc
carbon
carboxyl
group
n
n
atom
amino
group
atom
residu
within
ligand
calcul
along
md
trajectori
cc
n
atom
residu
stabl
lowest
standard
deviat
distanc
angl
dihedr
valu
select
three
receptor
atom
determin
mean
valu
distanc
angl
dihedr
use
ad
restraint
three
ligand
atom
three
receptor
atom
order
calcul
abf
valu
ligand
receptor
ligand
electrostat
van
der
waal
interact
decoupl
recent
publish
work
use
ad
restraint
use
decoupl
electrostat
interact
use
decoupl
vdw
interact
respect
need
lot
comput
resourc
thu
applic
virtual
screen
purpos
order
make
possibl
use
fepabf
rapid
discoveri
inhibitor
alchem
pathway
optim
find
one
significantli
improv
calcul
speed
also
keep
accuraci
accord
fep
theori
order
calcul
free
energi
differ
probabl
distribut
potenti
energi
differ
adjac
denot
sampl
report
studi
consid
gaussianlik
distribut
true
step
electrostat
interact
vdw
interact
decoupl
howev
restraint
addit
step
far
gaussian
distribut
studi
first
deriv
introduc
restrain
energi
distribut
red
function
use
correctli
describ
restraint
addit
step
use
automat
restrain
ad
program
describ
fit
red
function
restraint
energi
accur
estim
use
singlestep
perturb
directli
greatli
decreas
calcul
resourc
need
restraint
addit
decoupl
electrostat
vdw
interact
alchem
pathway
significantli
decreas
number
need
keep
accuraci
also
studi
procedur
done
fepabf
calcul
greatli
acceler
made
applic
fepabf
virtual
screen
possibl
alchem
pathway
determin
window
cycl
steepest
descent
energi
minim
first
carri
ps
simul
nvt
ensembl
along
langevin
dynam
temperatur
coupl
perform
heat
system
k
weak
posit
restraint
kjmolnm
appli
receptor
ligand
heavi
atom
simul
system
subsequ
equilibr
npt
ensembl
ps
posit
restraint
still
appli
follow
ns
unconstrain
product
simul
pressur
coupl
use
parrinellorahman
pressur
coupl
scheme
linc
constraint
algorithm
use
hbond
simul
particl
mesh
ewald
pme
algorithm
use
calcul
longrang
electrostat
interact
valu
sampl
along
unconstrain
simul
free
energi
differ
window
calcul
use
bennet
accept
ratio
bar
method
sever
research
report
fepabf
method
rel
accur
electr
neutral
ligand
net
charg
ligand
systemat
error
consid
mani
fda
approv
drug
electr
neutral
molecul
evalu
via
fepabf
calcul
group
net
charg
group
molecul
highest
bind
free
energi
select
bioassay
valid
data
process
analysi
perform
use
biaevalu
softwar
probabl
distribut
energi
differ
differ
window
calcul
describ
follow
restrain
energi
distribut
red
function
eq
deriv
detail
discuss
red
function
given
support
inform
si
section
red
function
correctli
describ
sampl
restrain
energi
distribut
greatli
increas
converg
calcul
shown
figur
sampl
yellow
dot
ad
restraint
fit
quit
well
red
function
red
line
use
target
ligand
test
set
use
automat
restrain
ad
program
fit
red
function
calcul
use
onestep
perturb
valu
good
correl
calcul
use
previous
report
perturb
r
larger
result
shown
figur
b
energi
differ
two
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
alchem
pathway
test
system
less
kcalmol
besid
use
onestep
perturb
calcul
restr
rl
alchem
pathway
calcul
annihil
also
optim
decreas
number
valu
need
detail
discuss
correct
ration
red
function
given
si
section
detail
result
comparison
onestep
perturb
perturb
given
si
section
detail
strategi
optim
alchem
pathway
calcul
annihil
given
si
section
effort
fepabf
accur
calcul
use
valu
need
comput
resourc
compar
report
fep
protocol
calcul
acceler
time
acceler
fepabf
calcul
first
made
possibl
appli
virtual
screen
rapidli
discov
inhibitor
coronaviru
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
accuraci
acceler
calcul
first
test
target
receptorligand
system
one
target
also
use
studi
fepabf
method
use
valu
previous
report
aldeghi
et
al
sinc
fepabf
calcul
systemat
bia
net
charg
ligand
neutral
ligand
aldeghi
work
use
studi
besid
target
two
target
includ
proteas
electr
neutral
ligand
human
factor
xa
electr
neutral
ligand
bind
mode
calcul
test
system
known
protein
data
bank
wwwrcsborg
ensur
correct
start
structur
given
detail
tabl
tabl
linear
regress
statist
calcul
experiment
result
given
tabl
copyright
holder
preprint
peerreview
fdaapprov
drug
dock
bind
site
mpro
molecul
specif
interact
six
key
amino
acid
residu
includ
figur
sinc
candesartan
cilextil
prodrug
metabolit
candesartan
also
prove
mpro
inhibitor
show
thu
total
activ
molecul
found
studi
structur
activ
shown
figur
inhibitori
curv
potent
lead
given
figur
among
activ
molecul
ten
lead
name
shown
black
figur
origin
discov
studi
six
compound
includ
disulfiram
chloroquin
montelukast
sodium
atazanavir
indinavir
maribavir
also
report
previou
studi
figur
dipyridamol
identifi
potent
mpro
inhibitor
first
discov
fepabf
method
addit
spr
assay
perform
determin
bind
affin
dipyridamol
mpro
vitro
reveal
dip
bound
mpro
experiment
confirm
affin
kd
eq
figur
short
rel
hit
rate
ten
origin
discov
lead
includ
dipyridamol
indic
signific
advantag
fepabf
method
discov
biolog
activ
compound
tradit
method
molecular
dock
molecular
dynam
simul
put
bind
pattern
dipyridamol
mpro
given
figur
shown
figur
hydrogen
bond
interact
hydrophob
interact
main
drive
forc
bind
dipyridamol
mpro
proteinligand
interact
fingerprint
plif
given
figur
show
key
residu
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
patient
subject
investig
therapeut
use
particularli
shadow
rapid
spread
world
report
led
increas
amount
proinflammatori
cytokin
serum
may
associ
pulmonari
inflamm
lung
damag
patient
viral
infect
host
pattern
recognit
receptor
prr
rigi
sens
viral
rna
hierarch
trigger
signal
cascad
includ
adaptor
protein
mav
traf
set
wellstudi
serinethreonin
kinas
ikk
complex
sever
transcript
factor
turn
transcript
antivir
type
interferon
ifn
proinflammatori
cytokin
gene
includ
subsequ
process
activ
inflammasom
becom
matur
initi
inflammatori
respons
figur
investig
function
activ
molecul
virusinduc
proinflammatori
cytokin
among
activ
molecul
figur
two
molecul
dipyridamol
montelukast
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sodium
inhibit
activ
induc
sev
infect
rigi
card
activ
form
rna
viral
receptor
rigi
overexpress
figur
addit
dipyridamol
montelukast
sodium
decreas
sevinduc
mrna
express
proinflammatori
cytokin
figur
interestingli
dipyridamol
montelukast
sodium
could
also
inhibit
activ
inflammasom
reduc
secret
figur
collect
found
dipyridamol
montelukast
sodium
show
global
inhibitori
function
signal
inflammatori
respons
viral
infect
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
plasmid
follow
dipyridamol
montelukast
sodium
treatment
cell
cultur
supernat
collect
hr
posttransfect
measur
releas
elisa
studi
acceler
fepabf
base
virtual
screen
strategi
bioassay
valid
introduc
rapid
protocol
accur
discov
proteinas
mpro
inhibitor
clinic
trial
regist
result
finish
firstround
clinic
trial
includ
patient
demonstr
markedli
improv
clinic
outcom
summari
fepabfebas
method
show
signific
advantag
mean
improv
hit
rate
reposit
potent
agent
especi
suitabl
prompt
drug
reposit
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
emerg
situat
outbreak
viru
mutat
also
import
drug
target
consid
situat
restraint
receptor
ligand
ad
equilibrium
posit
interact
receptor
ligand
consist
two
part
includ
forc
field
restraint
interact
come
forc
field
simplifi
harmon
potenti
sinc
ligand
near
equilibrium
restraint
forc
also
harmon
bias
forc
thu
total
interact
potenti
receptor
ligand
simplifi
appar
forc
constant
gener
distanc
current
posit
equilibrium
ad
restraint
adjac
sampl
order
calcul
free
energi
ad
restraint
repres
follow
equat
mean
adjac
th
th
window
forc
constant
ad
restraint
circumst
probabl
distribut
repres
z
partit
function
kbt
two
factor
use
combin
two
term
keep
function
describ
first
term
denot
harmon
energi
term
hereinaft
small
second
term
denot
gaussian
term
hereinaft
larg
two
constant
set
two
rel
big
integ
chose
respect
also
choos
valu
affect
fit
result
much
result
fit
red
function
discuss
detail
follow
section
si
section
although
accuraci
fep
calcul
report
sever
studi
calcul
resourc
need
singl
fepabf
predict
massiv
thu
order
rapidli
discov
function
fit
quit
well
converg
calcul
restraint
energi
greatli
improv
result
restraint
energi
accur
calcul
onestep
perturb
valu
chang
directli
calcul
greatli
acceler
use
proteaseligand
complex
crystal
structur
pdb
id
exampl
restraint
ad
use
onestep
perturb
perturb
respect
sampl
ad
restraint
fit
red
function
result
shown
figur
pictur
yellow
dot
correspond
sampl
green
line
harmon
energi
term
red
function
blue
line
gaussian
term
red
function
expect
red
function
describ
harmon
energi
term
small
gaussian
term
larg
sampl
fit
well
free
energi
ad
restraint
kcalmol
perturb
onestep
perturb
respect
mean
converg
onestep
perturb
pretti
good
order
justifi
applic
onestep
perturb
valu
denot
ad
restraint
three
differ
target
ligand
test
compar
restr
rl
result
calcul
bond
angl
dihedr
paramet
restraint
calcul
tabl
summar
result
restr
rl
calcul
result
reveal
singlestep
perturb
good
converg
energi
differ
test
system
less
kcalmol
thu
use
automat
restrain
ad
program
fit
sampl
red
function
calcul
resourc
need
ad
restraint
greatli
decreas
keep
accuraci
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
c
rl
refer
free
energi
differ
initi
state
perturb
specif
alchem
state
defin
rel
lambda
array
whose
alchem
pathway
defin
window
rl
refer
free
energi
differ
initi
state
perturb
specif
alchem
state
defin
rel
lambda
array
whose
alchem
pathway
defin
window
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
section
red
function
also
correctli
describ
restrain
energi
distribut
even
restrain
ad
equilibrium
posit
although
automat
restrain
ad
program
make
sure
paramet
chose
restrain
close
equilibrium
still
import
understand
behavior
probabl
distribut
paramet
equilibrium
exampl
determin
restraint
paramet
use
origin
crystal
structur
instead
use
preequilibr
trajectori
result
shown
figur
seen
probabl
distribut
initi
sever
window
show
distribut
doublepeak
shape
theori
doublepeak
shape
distribut
happen
rel
posit
receptor
ligand
use
determin
ligand
restraint
addit
paramet
far
equilibrium
state
time
harmon
potenti
use
appli
restraint
strong
enough
accord
fep
theori
probabl
distribut
near
lower
tail
greatli
influenc
accuraci
calcul
doublepeak
shape
probabl
distribut
far
equilibrium
distribut
pattern
near
lower
tail
vari
time
time
simul
result
unstabl
free
energi
estim
thu
deal
instabl
energi
calcul
report
studi
restraint
ad
valu
first
sever
select
rather
close
although
purpos
red
function
describ
restraint
ad
near
equilibrium
state
red
function
also
describ
well
even
restraint
ad
near
equilibrium
use
forward
perturb
exampl
shown
figur
ad
restrain
rel
weak
equilibrium
posit
peak
right
describ
gaussian
term
red
function
caus
ligand
occupi
equilibrium
posit
peak
left
caus
ad
restraint
describ
harmon
energi
term
red
function
red
function
describ
ad
restraint
quit
well
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
matter
whether
restraint
ad
near
equilibrium
prove
correct
ration
function
red
function
use
optim
give
deeper
understand
fepabf
calcul
futur
studi
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
section
fep
calcul
acceler
time
keep
accuraci
appropri
select
valu
order
acceler
calcul
studi
effect
decreas
number
valu
charg
vdw
interact
decoupl
use
differ
receptorligand
system
correspond
crystal
structur
pdb
code
use
order
make
sure
bind
mode
receptor
ligand
correct
crystal
structur
abf
first
calcul
use
restrain
charg
vdw
report
recent
publish
work
number
valu
decreas
decoupl
charg
vdw
interact
seen
tabl
use
valu
total
restrain
fit
red
function
charg
vdw
energi
calcul
result
quit
close
calcul
use
valu
system
test
energi
differ
within
kcalmol
compar
fepabf
calcul
use
valu
need
comput
resourc
calcul
acceler
time
acceler
fepabf
calcul
possibl
appli
virtual
screen
rapidli
discov
inhibitor
coronaviru
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
